- Home
- RBNE vs SBFM Comparison
RBNE vs SBFM Comparison
Compare RBNE & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBNE
- SBFM
- Stock Information
- Founded
- RBNE 2024
- SBFM 2006
- Country
- RBNE Cyprus
- SBFM United States
- Employees
- RBNE N/A
- SBFM N/A
- Industry
- RBNE Marine Transportation
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- RBNE Consumer Discretionary
- SBFM Health Care
- Exchange
- RBNE Nasdaq
- SBFM Nasdaq
- Market Cap
- RBNE 7.3M
- SBFM 6.6M
- IPO Year
- RBNE N/A
- SBFM N/A
- Fundamental
- Price
- RBNE $1.36
- SBFM $1.50
- Analyst Decision
- RBNE
- SBFM Strong Buy
- Analyst Count
- RBNE 0
- SBFM 1
- Target Price
- RBNE N/A
- SBFM $15.00
- AVG Volume (30 Days)
- RBNE 4.2M
- SBFM 44.4K
- Earning Date
- RBNE 09-23-2025
- SBFM 11-04-2025
- Dividend Yield
- RBNE N/A
- SBFM N/A
- EPS Growth
- RBNE N/A
- SBFM N/A
- EPS
- RBNE N/A
- SBFM N/A
- Revenue
- RBNE N/A
- SBFM $36,341,741.00
- Revenue This Year
- RBNE N/A
- SBFM $32.20
- Revenue Next Year
- RBNE N/A
- SBFM $32.74
- P/E Ratio
- RBNE N/A
- SBFM N/A
- Revenue Growth
- RBNE N/A
- SBFM 19.22
- 52 Week Low
- RBNE $1.32
- SBFM $1.17
- 52 Week High
- RBNE $20.57
- SBFM $3.90
- Technical
- Relative Strength Index (RSI)
- RBNE N/A
- SBFM 56.84
- Support Level
- RBNE N/A
- SBFM $1.35
- Resistance Level
- RBNE N/A
- SBFM $1.45
- Average True Range (ATR)
- RBNE 0.00
- SBFM 0.07
- MACD
- RBNE 0.00
- SBFM 0.01
- Stochastic Oscillator
- RBNE 0.00
- SBFM 82.39
About RBNE Robin Energy Ltd. Common Stock
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.